MCID: HYP020
MIFTS: 64

Hyperprolactinemia

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Reproductive diseases, Metabolic diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 53 12 72 71 36 28 51 41 14 69
Chiari-Frommel Syndrome 12 49 41 69
Hprl 53 71
Familial Isolated Prolactin Receptor Deficiency 55
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 55
Hyperprolactinaemia 12

Characteristics:

Orphanet epidemiological data:

55
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
hyperprolactinemia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 615555
Disease Ontology 12 DOID:12700
ICD10 32 E22.1
NCIt 46 C113168
Orphanet 55 ORPHA397685
ICD10 via Orphanet 33 E22.1
MedGen 39 C0020514
KEGG 36 H01388

Summaries for Hyperprolactinemia

OMIM : 53 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to mccune-albright syndrome and infertility, and has symptoms including osteopenia, osteoporosis and infertility. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Jak-STAT signaling pathway. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and ovary, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

UniProtKB/Swiss-Prot : 71 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Wikipedia : 72 Hyperprolactinaemia or hyperprolactinemia is the presence of abnormally high levels of prolactin in the... more...

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 250)
# Related Disease Score Top Affiliating Genes
1 mccune-albright syndrome 31.7 GH1 IGF1 PRL SST
2 infertility 30.4 GNRH1 PRL PRLR
3 peripartum cardiomyopathy 30.2 DRD2 PRL
4 hypogonadotropism 30.1 GNRH1 PRL
5 galactorrhea 30.1 DRD2 IGF1 PRL PRLR
6 polycystic ovary syndrome 30.0 GNRH1 IGF1 PRL
7 gigantism 30.0 GH1 GHRH PRL
8 ovarian disease 29.9 GNRH1 IGF1 PRL
9 amenorrhea 29.9 GNRH1 POMC PRL TRH
10 anovulation 29.9 GNRH1 IGF1 PRL
11 lymphocytic hypophysitis 29.8 GH1 POMC
12 tetrahydrobiopterin deficiency 29.7 GH1 PRL
13 central precocious puberty 29.7 GNRH1 IGF1
14 non-functioning pituitary adenoma 29.7 GH1 SST
15 fasting hypoglycemia 29.6 IGF1 POMC
16 growth hormone deficiency 29.6 GH1 GHRH IGF1
17 hyperandrogenism 29.5 GNRH1 IGF1 POMC PRL
18 adenoma 29.4 GH1 IGF1 POMC PRL SST
19 empty sella syndrome 29.4 GH1 GNRH1 POMC PRL TRH
20 fibrous dysplasia 29.3 GH1 IGF1 PRL SST
21 isolated growth hormone deficiency 29.3 GH1 GHRH IGF1
22 hyperthyroidism 29.1 GH1 PRL SST TRH
23 multiple endocrine neoplasia, type i 29.0 PRL SST VIP
24 chiasmal syndrome 29.0 GNRH1 POMC PRL SST
25 pituitary adenoma, prolactin-secreting 29.0 DRD2 GH1 IGF1 POMC PRL SST
26 pituitary tumors 28.9 GH1 IGF1 POMC PRL SST
27 insulin-like growth factor i 28.7 GH1 GHRH IGF1 PRL SST
28 adrenal gland hyperfunction 28.5 GH1 GHRH POMC PRL SST
29 hypopituitarism 28.5 GH1 GHRH GNRH1 IGF1 POMC PRL
30 functioning pituitary adenoma 28.4 DRD2 GH1 POMC PRL SST TRH
31 pituitary adenoma 28.4 GH1 GHRH IGF1 POMC PRL SST
32 acromegaly 28.4 GH1 GHRH IGF1 POMC PRL SST
33 body mass index quantitative trait locus 11 28.1 DRD2 GAL GH1 GHRH IGF1 POMC
34 amenorrhea-galactorrhea syndrome 11.4
35 ahumada del castillo syndrome 11.4
36 galactorrhoea-hyperprolactinaemia 11.1
37 fibrous dysplasia/mccune-albright syndrome 10.5 GH1 PRL
38 generalized resistance to thyroid hormone 10.5 PRL TRH
39 schizophreniform disorder 10.4 DRD2 PRL
40 social phobia 10.4 DRD2 PRL
41 suprasellar meningioma 10.4 POMC TRH
42 acth-secreting pituitary adenoma 10.4 POMC PRL
43 mammographic density 10.4 IGF1 PRL
44 endometriosis of uterus 10.3 GNRH1 PRL PRLR
45 aromatase deficiency 10.3 GH1 GNRH1
46 growth hormone secreting pituitary adenoma 10.3 PRL SST
47 bronchus adenoma 10.3 POMC SST
48 bronchial adenomas/carcinoids childhood 10.2 POMC SST
49 pituitary apoplexy 10.2 GNRH1 POMC PRL
50 sex differentiation disease 10.2 GNRH1 POMC PRL

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Symptoms via clinical synopsis from OMIM:

53
Genitourinary Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Chest Breasts:
galactorrhea (in some patients)

Endocrine Features:
elevated prolactin levels


Clinical features from OMIM:

615555

Human phenotypes related to Hyperprolactinemia:

55 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000938
2 osteoporosis 55 31 occasional (7.5%) Occasional (29-5%) HP:0000939
3 infertility 55 31 occasional (7.5%) Frequent (79-30%) HP:0000789
4 menorrhagia 55 31 occasional (7.5%) Occasional (29-5%) HP:0000132
5 galactorrhea 55 31 occasional (7.5%) Very frequent (99-80%) HP:0100829
6 female hypogonadism 55 31 occasional (7.5%) Occasional (29-5%) HP:0000134
7 amenorrhea 55 31 frequent (33%) Frequent (79-30%) HP:0000141
8 oligomenorrhea 55 31 occasional (7.5%) Very frequent (99-80%) HP:0000876
9 hemorrhagic ovarian cyst 55 31 frequent (33%) Frequent (79-30%) HP:0012886
10 prolactin excess 31 HP:0000870

MGI Mouse Phenotypes related to Hyperprolactinemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.17 DRD2 IGF1 GAL POMC GHRH PRL
2 homeostasis/metabolism MP:0005376 10.15 GNRH1 DRD2 IGF1 GAL POMC GHRH
3 growth/size/body region MP:0005378 10.1 GNRH1 DRD2 IGF1 GAL POMC GHRH
4 behavior/neurological MP:0005386 10.06 DRD2 GAL POMC PTHLH SST PRL
5 immune system MP:0005387 9.97 PRL GNRH1 DRD2 IGF1 POMC GHRH
6 adipose tissue MP:0005375 9.88 DRD2 IGF1 POMC PTHLH PRLR
7 integument MP:0010771 9.86 PRL GNRH1 DRD2 IGF1 GAL POMC
8 nervous system MP:0003631 9.7 GNRH1 DRD2 IGF1 GAL POMC GHRH
9 neoplasm MP:0002006 9.63 PRL GNRH1 DRD2 IGF1 POMC PRLR
10 reproductive system MP:0005389 9.28 GNRH1 DRD2 IGF1 GAL GHRH PRL

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Cabergoline Approved Phase 4 81409-90-7 54746
5
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Amantadine Approved Phase 4 768-94-5 2130
8 Antipsychotic Agents Phase 4,Phase 3,Phase 2
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2
11 Tranquilizing Agents Phase 4,Phase 3,Phase 2
12 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Dopamine Antagonists Phase 4,Phase 3
14 Dopamine D2 Receptor Antagonists Phase 4
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Paliperidone Palmitate Phase 4
17
Serotonin Phase 4,Phase 3 50-67-9 5202
18 Serotonin 5-HT2 Receptor Antagonists Phase 4
19 Serotonin Agents Phase 4,Phase 3
20 Serotonin Antagonists Phase 4,Phase 3
21 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
22 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1
24 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
25 Estradiol 17 beta-cypionate Phase 4
26 Estradiol 3-benzoate Phase 4
27 Estradiol valerate Phase 4 979-32-8
28 Polyestradiol phosphate Phase 4
29 Analgesics Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Infective Agents Phase 4
32 Antiviral Agents Phase 4
33
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
34
Calcium Carbonate Approved, Investigational Phase 3 471-34-1
35
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
37 Hormone Antagonists Phase 3,Phase 2
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
39 Antacids Phase 3
40 Anti-Ulcer Agents Phase 3
41 Bone Density Conservation Agents Phase 3
42 Calcium, Dietary Phase 3
43 Ergocalciferols Phase 3
44 Gastrointestinal Agents Phase 3
45 Micronutrients Phase 3
46 Trace Elements Phase 3
47 Vitamins Phase 3
48 Quetiapine Fumarate Phase 3 111974-72-2
49 Calciferol Nutraceutical Phase 3
50 Vitamin D2 Nutraceutical Phase 3

Interventional clinical trials:

(show all 35)

# Name Status NCT ID Phase Drugs
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
2 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
3 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
4 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
5 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
8 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
9 Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
10 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
11 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
12 Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Completed NCT00600756 Phase 3 Quetiapine XR;Risperidone
13 Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia Completed NCT01852331 Phase 2 PGD granules;Placebo
14 Administration of Kisspeptin in Patients With Hyperprolactinemia Recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
15 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
16 Administration of Kisspeptin to Subjects With Reproductive Disorders Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
17 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia Unknown status NCT02013232 Aripiprazole
18 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Cabergoline;cabergoline
19 TSH And AMH in Infertile Women Unknown status NCT02710175
20 Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine Completed NCT00952757
21 Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia Completed NCT01338298 Aripiprazole;Placebo
22 Characterization of Macroprolactinemia Completed NCT00436111
23 The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women Completed NCT01117272
24 Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) Completed NCT01270711 Study Drug
25 Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON Completed NCT02098668
26 The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events Completed NCT01052948
27 The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function Completed NCT00973557
28 Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy Completed NCT00399776
29 Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents Completed NCT00573716
30 Prevalence of Pregnancy in Polycystic Ovary Syndrome Completed NCT03157921
31 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
32 Assessing Fertility Potential in Female Cancer Survivors Recruiting NCT01143844
33 Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. Active, not recruiting NCT02092129
34 Pituitary Function and Spontaneous Intracranial Hypotension Active, not recruiting NCT02603549
35 Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment Withdrawn NCT00699530

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: chiari-frommel syndrome

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

# Genetic test Affiliating Genes
1 Hyperprolactinemia 28 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

38
Pituitary, Bone, Ovary, Breast, Endothelial, Testes, Thyroid

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 735)
# Title Authors Year
1
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia. ( 29403128 )
2018
2
Dopamine agonist withdrawal in hyperprolactinemia: when and how. ( 29124662 )
2018
3
Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. ( 29334291 )
2018
4
Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. ( 29043560 )
2018
5
Frequency of Macroprolactin in Hyperprolactinemia. ( 29394965 )
2018
6
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality. ( 28437810 )
2017
7
Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report. ( 28925774 )
2017
8
Re: Myocardial Recovery in Peripartum Cardiomyopathy after Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28114195 )
2017
9
Therapeutic effects of Schisandra chinensis on the hyperprolactinemia in rat. ( 28259983 )
2017
10
Cabergoline for hyperprolactinemia: getting to the heart of it. ( 28260205 )
2017
11
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( 28396166 )
2017
12
Idiopathic granulomatous mastitis associated with hyperprolactinemia: A nonoperative approach. ( 28845595 )
2017
13
Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. ( 28828544 )
2017
14
Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. ( 29241908 )
2017
15
Reply to: Hyperprolactinemia and Hirsutism in Patients without Polycystic Ovary Syndrome. ( 28761266 )
2017
16
Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder. ( 28273980 )
2017
17
Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. ( 27709470 )
2017
18
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
19
Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study. ( 29317896 )
2017
20
Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia. ( 28775691 )
2017
21
Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials. ( 28372526 )
2017
22
Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. ( 27773859 )
2017
23
Re: Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on Biventricular Assist Device. ( 28169846 )
2017
24
Pituitary gamma-aminobutyric acid receptor stimulation by carnitine may be a new strategy for antipsychotic-induced hyperprolactinemia. ( 28569425 )
2017
25
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia. ( 28320278 )
2017
26
Antipsychotic-induced hyperprolactinemia in Tourette syndrome. ( 28740637 )
2017
27
Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. ( 27671881 )
2017
28
Myocardial Recovery in Peripartum Cardiomyopathy After Hyperprolactinemia Treatment on BIVAD. ( 27748657 )
2017
29
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach. ( 28440197 )
2017
30
The central mechanism of risperidone-induced hyperprolactinemia. ( 28336493 )
2017
31
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. ( 28235557 )
2017
32
Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. ( 29112461 )
2017
33
Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. ( 28236625 )
2017
34
Effects of TNF-I+ on penile structure alteration in rats with hyperprolactinemia. ( 28763467 )
2017
35
An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? ( 28791188 )
2017
36
The mechanism of selfheal extract in treating hyperprolactinemia. ( 28946556 )
2017
37
Occurrence of hyperprolactinemia in children with subclinical hypothyroidism. ( 28529200 )
2017
38
Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders. ( 28966250 )
2017
39
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
40
Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia. ( 28670538 )
2017
41
Hyperprolactinemia with low dose of risperidone in a young female. ( 28558899 )
2017
42
Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. ( 28889207 )
2017
43
Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. ( 27438182 )
2016
44
Effects of pterostilbene on treating hyperprolactinemia and related mechanisms. ( 27508025 )
2016
45
Pityriasis Rotunda and Hyperprolactinemia. ( 27006018 )
2016
46
Pregabalin-induced hyperprolactinemia in a patient with fibromyalgia: A case report. ( 28275758 )
2016
47
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients. ( 27639124 )
2016
48
Hyperprolactinemia Secondary to Allergic Fungal Sinusitis Compressing the Pituitary Gland. ( 26998375 )
2016
49
Factors Influencing Disconnection Hyperprolactinemia and Reversal of Serum Prolactin after Pituitary Surgery in a Non-Functioning Pituitary Macroadenoma. ( 27540328 )
2016
50
Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. ( 27776952 )
2016

Variations for Hyperprolactinemia

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

71
# Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

ClinVar genetic disease variations for Hyperprolactinemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PRLR NM_001204316.1(PRLR): c.635A> G (p.His212Arg) single nucleotide variant Pathogenic rs398122522 GRCh37 Chromosome 5, 35070276: 35070276

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to KEGG:

36
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 Jak-STAT signaling pathway hsa04630
3 Prolactin signaling pathway hsa04917

Pathways related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 DRD2 GAL GHRH GNRH1 IGF1 POMC
2
Show member pathways
12.63 DRD2 GAL GH1 GHRH GNRH1 POMC
3
Show member pathways
12.32 GH1 GHRH GNRH1 IGF1
4
Show member pathways
11.99 GH1 PRL PRLR
5
Show member pathways
11.89 GH1 IGF1 POMC
6 11.66 GH1 IGF1 PRLR
7 11.42 GHRH POMC PTHLH VIP
8 11.25 GH1 IGF1 PTHLH
9
Show member pathways
10.95 POMC TRH
10
Show member pathways
10.94 GH1 PRL PRLR

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 GAL GH1 GHRH GNRH1 IGF1 POMC
2 secretory granule GO:0030141 9.43 GAL POMC TRH
3 extracellular region GO:0005576 9.4 GAL GH1 GHRH GNRH1 IGF1 POMC
4 endosome lumen GO:0031904 9.13 GH1 PRL PRLR

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 GHRH IGF1 PTHLH VIP
2 negative regulation of cell proliferation GO:0008285 9.8 DRD2 GAL GNRH1 PTHLH SST
3 response to ethanol GO:0045471 9.69 DRD2 GNRH1 TRH
4 female pregnancy GO:0007565 9.67 GNRH1 PRL PTHLH
5 cell-cell signaling GO:0007267 9.63 GHRH GNRH1 POMC PTHLH SST TRH
6 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.61 GHRH PTHLH VIP
7 G-protein coupled receptor signaling pathway GO:0007186 9.61 DRD2 GAL GHRH GNRH1 POMC PTHLH
8 adult walking behavior GO:0007628 9.57 DRD2 TRH
9 cAMP-mediated signaling GO:0019933 9.56 GAL GHRH
10 regulation of multicellular organism growth GO:0040014 9.55 IGF1 PRL
11 positive regulation of receptor internalization GO:0002092 9.54 DRD2 GH1
12 positive regulation of multicellular organism growth GO:0040018 9.54 DRD2 GH1 GHRH
13 positive regulation of JAK-STAT cascade GO:0046427 9.52 GH1 PRL
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.5 GH1 PRL PRLR
15 positive regulation of growth hormone secretion GO:0060124 9.48 DRD2 GHRH
16 adenohypophysis development GO:0021984 9.46 DRD2 GHRH
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 GHRH IGF1
18 regulation of receptor activity GO:0010469 9.36 GAL GH1 GHRH GNRH1 IGF1 POMC

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.33 GAL POMC VIP
2 hormone activity GO:0005179 9.32 GAL GH1 GNRH1 IGF1 POMC PRL
3 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....